Search results for "Inflammatory bowel disease"
MKSAP Quiz: Watery, nonbloody diarrhea and abdominal pain
This month's quiz asks readers to determine the most appropriate diagnostic test to perform in a 25-year-old patient with watery, nonbloody diarrhea of 9 months' duration, usually accompanied by abdominal pain in the periumbilical area or left lower quadrant.
https://gastroenterology.acponline.org/archives/2022/04/22/4.htm
22 Apr 2022
Review finds only two efficacious medications to treat gastroparesis
Clebopride ranked first for efficacy, followed by domperidone, and no other drug was superior to placebo for improving symptoms of gastroparesis, according to a recent meta-analysis.
https://gastroenterology.acponline.org/archives/2023/01/27/2.htm
27 Jan 2023
Spotlight on the cost of gastroenteritis
Two industry-funded studies looked at the economic burden of acute infectious gastroenteritis among U.S. adults and found that use of large multiplex polymerase chain reaction panels was associated with similar costs as traditional workup.
https://gastroenterology.acponline.org/archives/2023/02/24/5.htm
24 Feb 2023
In active UC, upadacitinib induced and maintained remission
JAK inhibitors, such as upadacitinib, represent an advance in the management of patients with ulcerative colitis (UC); however, it remains unclear whether the balance of efficacy versus risk favors one drug over the others, according to an ACP Journal Club commentary.
https://gastroenterology.acponline.org/archives/2022/10/28/11.htm
28 Oct 2022
Spotlight on colorectal neoplasia in IBD
Recent research focused on colorectal neoplasia in patients with inflammatory bowel disease (IBD), identifying both risk factors, including a novel association with cigarette smoke exposure, and protective factors.
https://gastroenterology.acponline.org/archives/2021/01/22/5.htm
22 Jan 2021
Guidance offered for managing colorectal dysplasia in patients with IBD
Among other best practice advice from the American Gastroenterological Association, precancerous colorectal lesions in patients with inflammatory bowel disease (IBD) should be described as polypoid, nonpolypoid, or invisible using a modified Paris Classification.
https://gastroenterology.acponline.org/archives/2021/09/24/1.htm
24 Sep 2021
Infliximab or tofacitinib for IBD associated with lower response to COVID-19 vaccination
An industry-funded study in England looked at SARS-CoV-2 antibody concentrations after two vaccine doses among patients taking infliximab, tofacitinib, thiopurine, ustekinumab, or vedolizumab for inflammatory bowel disease (IBD), comparing them to healthy controls.
https://gastroenterology.acponline.org/archives/2022/02/25/1.htm
25 Feb 2022
Spotlight on COVID-19 vaccines in IBD
Recent research looked at the response to mRNA COVID-19 vaccines among patients with inflammatory bowel disease (IBD), as well as examined COVID-19 vaccine uptake and offered ways to address vaccine hesitancy in this population.
https://gastroenterology.acponline.org/archives/2021/10/22/5.htm
22 Oct 2021
MKSAP Quiz: VTE prophylaxis during hospitalization for ulcerative colitis
This month's quiz asks readers to determine the appropriate venous thromboembolism (VTE) prophylaxis in a 30-year-old man hospitalized for an acute flare of ulcerative colitis.
https://gastroenterology.acponline.org/archives/2021/08/27/4.htm
27 Aug 2021
Spotlight on IBD therapy effects
Research in the past month found that infliximab blunts the body's immune response to COVID-19 infection, that both infliximab and adalimumab are effective in long-term treatment of outpatients with inflammatory bowel disease (IBD), and that antitumor necrosis factor therapy may be associated with reduced mortality compared with long-term corticosteroid use in patients with Crohn's disease.
https://gastroenterology.acponline.org/archives/2021/03/26/5.htm
26 Mar 2021